The Open AIDS Journal

ISSN: 1874-6136 ― Volume 10, 2016

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data

Allan E Rodriguez 1, Edwin DeJesus 2, Vanessa Williams 3, David Irlbeck 3, Lisa Ross 3, Belinda Ha*, 3 , Charles T Lancaster 3
1 University of Miami, Miami, Florida
2 Orlando Immunology Center, Orlando, Florida
3 GlaxoSmithKline, Research Triangle Park, North Carolina, USA


In HBV/HIV-coinfected patients, the risk of end-stage liver disease and death is increased. This open-label, prospective, pilot study evaluated abacavir/lamivudine/zidovudine twice daily plus tenofovir once daily in HBV/HIV-coinfected antiretroviral-naïve subjects. Nine adults (8 males) enrolled, with baseline mean HIV-1 RNA = 4.5 log10 copies/mL, HBV DNA = 9.0 log10 copies/mL, and median CD4 count =158 cells/mm3. No subject had baseline ALT >5x ULN.

Six subjects completed the study: 1 withdrew due to non-treatment-related toxoplasmosis and 2 were lost-to-follow-up. At week 48, 100% (6/6) of remaining subjects had ≥2 log10 decrease in HBV DNA, and 100% (6/6) and 83% (5/6) had HIV-1 RNA <400 and <50 copies/mL, respectively. Median change from baseline in CD4 count was 157 cells/mm3. One subject experienced treatment-related grade 3 leukopenia. These results demonstrate that abacavir/lamivudine/zidovudine and tenofovir were well tolerated with sustained HIV-1 and HBV antiviral activity through 48 weeks in HBV/HIV-coinfected, antiretroviral-naïve subjects.

Keywords: HIV, coinfection, hepatitis B, abacavir, lamivudine, zidovudine, tenofovir..

Article Information

Identifiers and Pagination:

Year: 2010
Volume: 4
First Page: 167
Last Page: 170
Publisher Id: TOAIDJ-4-167
DOI: 10.2174/1874613601004010167

Article History:

Received Date: 24/5/2010
Revision Received Date: 15/7/2010
Acceptance Date: 17/8/2010
Electronic publication date: 21/10/2010
Collection year: 2010

© Rodriguez et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709, USA; Tel: 919-483-8284; Fax: 919-256-5053; E-mail:


"Publishing with Bentham Open was a great experience. The timeliness and communication were outstanding. I am hopeful that I will have the opportunity to publish with Bentham Open again in the future."

Dr. Daniel B. Chastain
Pharm.D., AAHIVP, Clinical Pharmacy Specialist, Infectious Diseases, Phoebe Health, USA

SCImago Journal Ranking

SCImago Journal & Country Rank

Browse Contents

Webmaster Contact:
Copyright © 2016 Bentham Open